A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection

被引：0
|
作者：
Gane, Edward [1 ]
Sevinsky, Heather [2 ]
Yuen, Man-Fung [3 ]
Anderson, Mark [4 ]
Cloherty, Gavin [4 ]
Thi, Emily P. [2 ]
Wattamwar, Tosh [2 ]
Sofia, Michael J. [2 ]
Gray, Kevin [2 ]
Antoniello, Deana [2 ]
Eley, Timothy [2 ]
Picchio, Gaston [2 ]
Sims, Karen [2 ]
机构：
[1] Univ Auckland, Auckland, New Zealand
[2] Arbutus Biopharma, Warminster, PA USA
[3] Queen Mary Hosp, Hong Kong, Peoples R China
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PO-2879
引用
收藏
页码：S762 / S763
页数：2
相关论文
共 16 条
  • [11]  HBeAg negative chronic hepatitis B patients with normal ALT and positive HBV DNA can benefit from nucleos(t)ide analogue therapy: results of a single center retrospective study with long-term follow-up
    Chen, En-Qiang
    Zhou, Jing
    Wang, Fa-Da
    Li, Lan-Qing
    GUT, 2023, 72 (SUPPL_1) : A159 - A159
  • [12] HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos (t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B
    van Boemmel, Florian
    Deichsel, Danilo
    Loglio, Alessandro
    Facchetti, Floriana
    Pfefferkorn, Maria
    Brehm, Martin
    Berg, Thomas
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E487 - E487
  • [13] Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos (t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients
    Ohlendorf, Valerie
    Wuebbolding, Maximilian
    zu Siederdissen, Christoph Hoener
    Bremer, Birgit
    Deterding, Katja
    Wedemeyer, Heiner
    Cornberg, Markus
    Maasoumy, Benjamin
    JOURNAL OF HEPATOLOGY, 2022, 77 : S248 - S249
  • [14] Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy
    Carey, Ivana
    Gersch, Jeffrey
    Wang, Bo
    Moigboi, Christiana
    Kuhns, Mary
    Cloherty, Gavin
    Dusheiko, Geoffrey
    Agarwal, Kosh
    HEPATOLOGY, 2020, 72 (01) : 42 - 57
  • [15] Limited Sustained Response and Lack of HBsAg Decline after Stopping Long-Term Nucleos(t)Ide Analogue Therapy in Hbeag Negative Patients with Chronic Hepatitis B: Results of a Prospective, Randomized, Open-Label Phase IV Trial
    Liem, Kin Seng
    Fung, Scott K.
    Wong, David K. H.
    Yim, Colina K.
    Noureldin, Seham
    Huang, Feng Fei
    Shah, Hemant A.
    Feld, Jordan J.
    Hansen, Bettina E.
    Janssen, Harry L. A.
    HEPATOLOGY, 2018, 68 : 165A - 165A
  • [16] ADDITION OF PEGINTERFERON ALFA-2a INCREASES HBsAg DECLINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY: RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL. (PAS STUDY)
    Farag, Mina S.
    Fung, Scott K.
    Van Campenhout, Margo
    Van Erpecum, Karel J.
    Wong, David K. H.
    Boonstra, Andre
    Verhey, Elke
    De Man, Robert A.
    Liem, Kin Seng
    Hansen, Bettina E.
    Janssen, Harry L. A.
    HEPATOLOGY, 2019, 70 : 127A - 128A
12